Anthony Jeffrey

Increased Atrial 18F-FDG Uptake on PET/CT Secondary to Atrial Flutter Precipitated by Ibrutinib

Anthony Jeffrey, C Brown, Luke Coyle, Elizabeth Bernard

We report a case of marked biatrial 18 F-FDG uptake on PET/CT coinciding with the onset of symptomatic atrial flutter in a 77-year-old man with relapsed diffuse large B-cell lymphoma receiving ibrutinib. Serial imaging demonstrated normal atrial uptake before arrhythmia, marked uptake …

au (code pays fourni par la source)

Time of infusion does not significantly impact outcomes following CAR T-cell therapy in large B-cell lymphoma

Mark R. Dowling, Edward R. Scheffer Cliff, Anthony Jeffrey, Catelyn Cashion et autres

ABSTRACT: In this retrospective analysis of 584 patients who received chimeric antigen receptor T-cell therapy for large B-cell lymphoma at 6 Australian centers, no association was found between time of infusion and outcome, accounting for confounders, suggesting minimal clinical impact of chronobiology …

au, us (code pays fourni par la source)

Flow cytometry immunophenotyping and cytogenetic analysis on disaggregated bone marrow trephine biopsies

Anthony Jeffrey, M Y Choy, Nisha Singh, Kit Double et autres

Flow cytometry immunophenotyping (FCI) and cytogenetic analysis are important diagnostic and prognostic investigations performed on bone marrow biopsy specimens. When particulate aspirate samples are not obtained, trephine samples can be disaggregated to yield cellular material for analysis. In this study, we assessed …

au (code pays fourni par la source)

The spectrum of tonsillar involvement in chronic lymphocytic leukemia (CLL)

Anthony Jeffrey, George Mason, Luke Coyle, Naomi Mackinlay et autres

Tonsillar enlargement in chronic lymphocytic leukemia (CLL) either with or without symptoms has been rarely reported. We describe 22 cases of CLL with tonsillar involvement and demonstrate this is a CLL disease site that may be under-recognized in routine practice. Tonsillar involvement …

au, nz, hk, us (code pays fourni par la source)

Real-world outcomes with CAR T-cell therapy for secondary central nervous system lymphoma are similar between patients with active versus historical involvement

Catelyn Cashion, Jian Li, Sergio Farina, Shafqat Inam et autres

Abstract Background: Secondary central nervous system large B-cell lymphoma (sCNSL) carriers a poor prognosis and is often refractory to standard chemoimmunotherapy. Autologous anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy has revolutionised the treatment of relapsed and/or refractory large B-cell lymphoma (LBCL) but …

au, us (code pays fourni par la source)

A simple scoring system for response and toxicity following lymphoma CAR-T: Results from the Australian CAR-T real-world consortium

Mark R. Dowling, Vinay Vanguru, Stephen Boyle, Catelyn Cashion et autres

Abstract Aim: Autologous anti-CD19 chimeric antigen receptor T-cell therapy (CAR-T) is now a standard-of-care for relapsed and/or refractory (R/R) large B-cell lymphoma (LBCL), but optimal patient selection, sequencing with other novel agents and bridging strategies are areas for improvement. Tisagenlecleucel (tisa-cel) and …

au, us (code pays fourni par la source)

Multi-centre real-world outcome of patients with Richter transformation receiving CD19-directed commercial CAR T-cell therapy in Australia.

Jian Li, Mark R. Dowling, Anthony Jeffrey, Sergio Farina et autres

Abstract Aim: Richter transformation (RT) is an uncommon (2-10%) complication of chronic lymphocytic leukemia (CLL), most frequently manifesting as diffuse large B-cell lymphoma (RT-DLBCL, 90-95%). It is associated with complex genetic aberrations and poor prognosis, with a median overall survival (OS) of …

au, us (code pays fourni par la source)

Real-world Australian experience with tisagenlecleucel for relapsed/refractory diffuse large B-cell lymphoma—importance of pre-CAR-T optimization

Phoebe Joy Ho, Vinay Vanguru, C. Burge, Rebecca Wayte et autres

Introduction Up to 50% of patients with diffuse large B-cell lymphoma (DLBCL) relapse or are refractory to first-line therapy. Tisagenlecleucel, a CD19-directed chimeric antigen receptor (CAR)-T cell therapy, is approved for patients with relapsed/refractory (r/r) DLBCL in the third-line setting. Patients with …

au (code pays fourni par la source)

Spontaneous remission of Epstein-Barr virus positive diffuse large B-cell lymphoma after relapse post axicabtagene ciloleucel chimeric antigen receptor T-cell therapy

Anthony Jeffrey, James Favaloro, Grace Wolyncewicz, Lisa Horgan et autres

Diffuse large B-cell lymphoma (DLBCL) is the most common histological subtype of non-Hodgkin lymphoma (NHL). Combination chemo-immunotherapy with R-CHOP (rituximab, cyclophosphamide, doxorubicin, v...

au, nz (code pays fourni par la source)

Flow cytometry immunophenotyping and cytogenetic analysis on disaggregated bone marrow trephine biopsies

Anthony Jeffrey, M Y Choy, Nisha Singh, Kit Double et autres

au (code pays fourni par la source)

Central Nervous System (CNS) T-Cell Lymphoma as the Presenting Manifestation of Late-Onset Combined Immunodeficiency

Anthony Jeffrey, Luke Coyle, Dishan Samaranayake, Thérèse Boyle et autres

Late-onset combined immunodeficiency (LOCID), considered now a subset of common variable immunodeficiency (CVID) disorders, is characterized by a predominantly T-cell immune defect. LOCID has a distinct phenotype from CVID with a greater risk of lymphoproliferative complications. As compared to the CVID cohort, …

au (code pays fourni par la source)

Bone marrow pseudo‐Gaucher cells demonstrating haemophagocytosis associated with extranodal NK /T cell lymphoma, nasal type

Anthony Jeffrey, George Mason, Ian Kerridge, Poomahal Kumar

A 30 year old female presented with a 4 month history of an enlarging right posterior thigh mass. Biopsy of the lesion demonstrated an angioinvasive atypical lymphoid infiltrate with pleomorphic nuclei and prominent nucleoli. The immunohistochemical profile was consistent with a diagnosis …

au (code pays fourni par la source)